Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrochlorothiazide

FDA-approved product (tablet, oral), marketed as Esidrix, Hydro-D, Hydrochlorothiazide and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrochlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with other drugs
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrochlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrochlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus

    NCT00526279 · start 2007-06

    Registered record
    Registry ID
    NCT00526279
    Conditions
    Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-06
    Completion
    2008-08
    Enrolment
    9,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria

    NCT01375322 · start 2007-06

    Registered record
    Registry ID
    NCT01375322
    Conditions
    Hypertension; Diabetes Mellitus, Type 2; Albuminuria
    Interventions
    Amlodipine+Benazepril; Valsartan+Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2010-06
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus, Type 2; Albuminuria
    InterventionAmlodipine+Benazepril; Valsartan+Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH

    NCT00607633 · start 2007-01

    Registered record
    Registry ID
    NCT00607633
    Conditions
    Essential Hypertension; Left Ventricular Hypertrophy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-10
    Enrolment
    686

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Left Ventricular Hypertrophy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

    NCT01020214 · start 2006-11

    Registered record
    Registry ID
    NCT01020214
    Conditions
    Healthy
    Interventions
    Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-11
    Completion
    2006-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOlmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mg
    PhasePhase 1
    Registry statusCompleted

  • A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

    NCT00368277 · start 2006-09

    Registered record
    Registry ID
    NCT00368277
    Conditions
    Hypertension
    Interventions
    Aliskiren; Ramipril; Hydrochlorothiazide; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09
    Completion
    2008-02
    Enrolment
    901

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAliskiren; Ramipril; Hydrochlorothiazide; Amlodipine
    PhasePhase 3
    Registry statusCompleted

  • Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

    NCT00326768 · start 2006-05

    Registered record
    Registry ID
    NCT00326768
    Conditions
    Hypertension
    Interventions
    Telmisartan 40 mg/HCTZ 12.5 mg; Telmisartan 40 mg; Telmisartan 80 mg/HCTZ 12.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-08
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan 40 mg/HCTZ 12.5 mg; Telmisartan 40 mg; Telmisartan 80 mg/HCTZ 12.5 mg
    PhasePhase 3
    Registry statusCompleted

  • Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

    NCT00311155 · start 2006-03

    Registered record
    Registry ID
    NCT00311155
    Conditions
    Essential Hypertension
    Interventions
    olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-04
    Enrolment
    694

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    Interventionolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
    PhasePhase 4
    Registry statusCompleted

  • I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

    NCT00362037 · start 2006-03

    Registered record
    Registry ID
    NCT00362037
    Conditions
    Hypertension
    Interventions
    Irbesartan (Aprovel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-06
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan (Aprovel)
    PhasePhase 4
    Registry statusCompleted

  • Renin Profiling in Selection of Initial Antihypertensive Drug

    NCT00834600 · start 2005-12

    Registered record
    Registry ID
    NCT00834600
    Conditions
    Hypertension
    Interventions
    olmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-12
    Completion
    2011-10
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartan
    PhaseNot applicable
    Registry statusCompleted

  • Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

    NCT00273299 · start 2005-11

    Registered record
    Registry ID
    NCT00273299
    Conditions
    Hypertension
    Interventions
    valsartan plus hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-07
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionvalsartan plus hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)

    NCT00546052 · start 2005-09-01

    Registered record
    Registry ID
    NCT00546052
    Conditions
    Hypertension; Metabolic Disorder
    Interventions
    losartan potassium (+) hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09-01
    Completion
    2008-01-01
    Enrolment
    1,738

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Metabolic Disorder
    Interventionlosartan potassium (+) hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

    NCT00656331 · start 2005-08

    Registered record
    Registry ID
    NCT00656331
    Conditions
    Hypertension
    Interventions
    Amlodipine and Hydrocholorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2005-08
    Completion
    2012-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine and Hydrocholorothiazide
    PhaseNot applicable
    Registry statusWithdrawn

  • Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

    NCT00146341 · start 2005-04

    Registered record
    Registry ID
    NCT00146341
    Conditions
    Hypertension
    Interventions
    Telmisartan/HCTZ; Telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-09
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan/HCTZ; Telmisartan
    PhasePhase 3
    Registry statusCompleted

  • PHARES Study: Management of Resistant Hypertension

    NCT00224549 · start 2005-04

    Registered record
    Registry ID
    NCT00224549
    Conditions
    Hypertension
    Interventions
    irbesartan, amlodipine and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2009-08
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionirbesartan, amlodipine and hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Antiproteinuric Effect of Valsartan and Lisinopril

    NCT00171574 · start 2004-11

    Registered record
    Registry ID
    NCT00171574
    Conditions
    Hypertension; Diabetic Nephropathy
    Interventions
    Valsartan; Valsartan plus HCTZ; Lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2006-07
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetic Nephropathy
    InterventionValsartan; Valsartan plus HCTZ; Lisinopril
    PhasePhase 4
    Registry statusCompleted